Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 7,493 calls trading, 2x expected, and implied vol increasing almost 4 points to 94.34%. Jan-25 6 calls and Jun-25 7 calls are the ...

Earnings call Recursion ended Q2 2025 with $533M in cash, a 35% reduction in expected cash burn by 2026 versus 2024, and reaffirmed guidance for over $100M in partnership inflows by end of 2026. The ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide ...

Recursion narrowly beat EPS expectations, signaling effective cost management. Revenue fell short by 69.44%, raising concerns about growth prospects. The company maintains a strong cash position with ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, delighted to be joining you on our L(earnings) today. And I'm joined by our Chief R&D and Commercial Officer, Najat Khan and ...